Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
MET Antibody, AUTS9 Antibody, C-Met Antibody, HGF/SF receptor Antibody, HGFR Antibody, Met kinase Antibody, Proto-oncogene c-Met Antibody, Scatter factor receptor Antibody, SF receptor Antibody, HGF receptor Antibody, RCCP2 Antibody, Tyrosine-protein kinase Met Antibody
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules.
Detection of endogenous Met in HepG2 cell line. 10 ug/lane of HepG2 cell lysate was used to examine the expression of human Met. Lanes 1-5 represent different anti-Met monoclonal antibodies. Lane 6 represents auto-phosphorylated-Met in HepG2 cell line detected by anti-phospho-Met antibody.
Western blot of lysates from HepG2, H. liver, HT-29 cell line (from left to right), using MET/HGFR Antibody(4AT247. 86. 63). 4AT247. 86. 63 was diluted at 1:1000 at each lane. A goat anti-mouse IgG H&L (HRP) at 1:3000 dilution was used as the secondary antibody. Lysates at 35ug per lane.